TD Cowen analyst Josh Jennings maintained a Buy rating on Abbott Laboratories today and set a price target of $145.00.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Josh Jennings has given his Buy rating due to a combination of factors that indicate strong performance and future potential for Abbott Laboratories. The company’s Q3 results were solid, with revenue and earnings per share aligning closely with market expectations. Notably, the Medical Devices segment showed impressive growth, with a 12.5% increase, driven by strong performance in Diabetes Care. This growth highlights the company’s ability to excel in high-demand areas.
Additionally, Abbott Laboratories has maintained its full-year guidance for organic sales growth, excluding COVID-related sales, at 7.5-8%, and has expressed confidence in meeting 2026 market estimates. The company’s ability to uphold its earnings guidance, despite challenges in certain markets, such as China, further underscores its resilience and operational strength. These factors collectively support the Buy rating, as they suggest a promising outlook for the company’s financial health and market position.
According to TipRanks, Jennings is a 3-star analyst with an average return of 1.2% and a 46.99% success rate. Jennings covers the Healthcare sector, focusing on stocks such as TransMedics Group, Boston Scientific, and Medtronic.